Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15109021 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL29726985 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL20048841 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL29404871 | 0.81 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL2197905 | 0.81 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL18331401 | 0.79 | ALDH1A1 (0.41) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL8274402 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL20048803 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TSHRTDP1PNMTCHRM5 | |
| SCHEMBL17071828 | 0.75 | TSHR (0.44) | ALDH1A1TSHR | |
| SCHEMBL4592337 | 0.75 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1PNMTCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117757763-A | Sulfoxide reductase mutant and application thereof in chiral sulfoxide preparation | 遵义医科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | Oxford Drug Design Limited (GB) | 2023-10-31 | — | — | US | disclosed |
| CN-114657580-B | Electrocatalytic diazonium salt methyl sulfoxide method and methyl sulfoxide derivative | 武汉纺织大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-114657580-A | Electrocatalytic diazoate methylsulfonylation method and methyl sulfoxide derivative | 武汉纺织大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-105709826-B | The preparation method and catalyst of a kind of corproporphyrin catalyst that axial direction is immobilized and application | 中国科学院大连化学物理研究所 | 2018-08-21 | — | — | CN | disclosed |
| WO-2018065611-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | Oxford Drug Design Limited (GB) | 2018-04-12 | — | — | WO | disclosed |
| EP-1765348-B1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-08-03 | — | — | EP | disclosed |
| CN-105709826-A | Preparation method of axially-immobilized porphyrin-like catalyst, catalyst and application of catalyst | 中国科学院大连化学物理研究所 | 2016-06-29 | — | — | CN | disclosed |
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-1673087-B1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-1846419-B1 | Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2014-04-16 | — | — | EP | disclosed |
| US-7776582-B2 | for gas chromatography; identifying an optically enhanced chiral ionic liquid (OCIL) for enantiomeric resolution | SIGMA-ALDRICH CO. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776582-B2 | for gas chromatography; identifying an optically enhanced chiral ionic liquid (OCIL) for enantiomeric resolution | SIGMA-ALDRICH CO. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090145197-A1 | Optically Enhanced Chiral Ionic Liquids | SIGMA-ALDRICH CO. NEWCO INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090145197-A1 | Optically Enhanced Chiral Ionic Liquids | SIGMA-ALDRICH CO. NEWCO INC. | 2009-06-11 | — | — | US | disclosed |
| US-5409893-A | Administering with platinum complexes | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-04-25 | — | — | US | disclosed |
| EP-0471709-B1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA (IT) | 1994-11-30 | — | — | EP | disclosed |
| EP-0471709-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS. | BOEHRINGER MANNHEIM ITALIA (IT) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990013553-A1 | RUTHENIUM(III) COMPLEXES AS ANTINEOPLASTIC AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802110-B2 | 2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase | AARS1, NSUN3, GARS1 | ALDH1A1 1814/4885TSHR 1674/4885TDP1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.